Sarcoidosis-associated pulmonary hypertension due to pulmonary arteries stenosis - a case report.
Balloon pulmonary angioplasty
Corticosteroids
Pulmonary hypertension
SAPH
Sarcoidosis
Treatment
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
16 Jul 2024
16 Jul 2024
Historique:
received:
15
04
2024
accepted:
08
07
2024
medline:
17
7
2024
pubmed:
17
7
2024
entrez:
16
7
2024
Statut:
epublish
Résumé
Sarcoidosis-associated pulmonary hypertension (SAPH) is listed in Group 5 of the clinical classification of pulmonary hypertension, due to its complex and multifactorial pathophysiology. The most common cause of SAPH development is advanced lung fibrosis with the associated destruction of the vascular bed, and/or alveolar hypoxia. However, a substantial proportion of SAPH patients (up to 30%) do not have significant fibrosis on chest imaging. In such cases, the development of pulmonary hypertension may be due to the lesions directly affecting the pulmonary vasculature, such as granulomatous angiitis, pulmonary veno-occlusive disease, chronic thromboembolism or external compression of vessels by enlarged lymph nodes. Based on the case of a 69-year-old female who developed SAPH due to pulmonary arteries stenosis, diagnostic difficulties and therapeutic management are discussed. The patient, non-smoking female, diagnosed with stage II sarcoidosis twelve years earlier, presented with progressive dyspnoea on exertion, dry cough, minor haemoptysis and increasing oedema of the lower limbs. Computed tomography pulmonary angiography (CTPA) showed complete occlusion of the right upper lobe artery and narrowing of the left lower lobe artery, with post-stenotic dilatation of the arteries of the basal segments. The vascular pathology was caused by adjacent, enlarged lymph nodes with calcifications and fibrotic tissue surrounding the vessels. Pulmonary artery thrombi were not found. The patient was treated with systemic corticosteroid therapy and subsequently with balloon pulmonary angioplasty. Partial improvement in clinical status and hemodynamic parameters has been achieved. An appropriate screening strategy is required for early detection of pulmonary hypertension in sarcoidosis patients. Once SAPH diagnosis is confirmed, it is crucial to determine the appropriate phenotype of pulmonary hypertension and provide the most effective treatment plan. Although determining SAPH phenotype is challenging, one should remember about the possibility of pulmonary arteries occlusion.
Sections du résumé
BACKGROUND
BACKGROUND
Sarcoidosis-associated pulmonary hypertension (SAPH) is listed in Group 5 of the clinical classification of pulmonary hypertension, due to its complex and multifactorial pathophysiology. The most common cause of SAPH development is advanced lung fibrosis with the associated destruction of the vascular bed, and/or alveolar hypoxia. However, a substantial proportion of SAPH patients (up to 30%) do not have significant fibrosis on chest imaging. In such cases, the development of pulmonary hypertension may be due to the lesions directly affecting the pulmonary vasculature, such as granulomatous angiitis, pulmonary veno-occlusive disease, chronic thromboembolism or external compression of vessels by enlarged lymph nodes. Based on the case of a 69-year-old female who developed SAPH due to pulmonary arteries stenosis, diagnostic difficulties and therapeutic management are discussed.
CASE PRESENTATION
METHODS
The patient, non-smoking female, diagnosed with stage II sarcoidosis twelve years earlier, presented with progressive dyspnoea on exertion, dry cough, minor haemoptysis and increasing oedema of the lower limbs. Computed tomography pulmonary angiography (CTPA) showed complete occlusion of the right upper lobe artery and narrowing of the left lower lobe artery, with post-stenotic dilatation of the arteries of the basal segments. The vascular pathology was caused by adjacent, enlarged lymph nodes with calcifications and fibrotic tissue surrounding the vessels. Pulmonary artery thrombi were not found. The patient was treated with systemic corticosteroid therapy and subsequently with balloon pulmonary angioplasty. Partial improvement in clinical status and hemodynamic parameters has been achieved.
CONCLUSIONS
CONCLUSIONS
An appropriate screening strategy is required for early detection of pulmonary hypertension in sarcoidosis patients. Once SAPH diagnosis is confirmed, it is crucial to determine the appropriate phenotype of pulmonary hypertension and provide the most effective treatment plan. Although determining SAPH phenotype is challenging, one should remember about the possibility of pulmonary arteries occlusion.
Identifiants
pubmed: 39014431
doi: 10.1186/s12890-024-03152-0
pii: 10.1186/s12890-024-03152-0
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
346Informations de copyright
© 2024. The Author(s).
Références
Statement on Sarcoidosis. https://doi.org/10.1164/ajrccm.160.2.ats4-99?role=tab . Accessed 7 Aug 2023.
Błasińska K, Jędrych ME, Opoka L, Tomkowski W, Szturmowicz M. Imaging plays a key role in the diagnosis and control of the treatment of Bone Sarcoidosis. Biomedicines. 2023;11:1866.
pubmed: 37509505
pmcid: 10377349
doi: 10.3390/biomedicines11071866
Zimna K, Szturmowicz M, Sobiecka M, Błasińska K, Bartosiewicz M, Tomkowski WZ. Sudden vision loss due to Optic Neuritis—An uncommon presentation of Neurosarcoidosis. Diagnostics. 2023;13:2579.
pubmed: 37568942
pmcid: 10417309
doi: 10.3390/diagnostics13152579
Tana C, Mantini C, Donatiello I, Mucci L, Tana M, Ricci F, et al. Clinical features and diagnosis of Cardiac Sarcoidosis. J Clin Med. 2021;10:1941.
pubmed: 34062709
pmcid: 8124502
doi: 10.3390/jcm10091941
Gupta R, Kim JS, Baughman RP. An expert overview of pulmonary fibrosis in sarcoidosis. Expert Rev Respir Med. 2023;17:119–30.
pubmed: 36861987
doi: 10.1080/17476348.2023.2183193
Kirkil G, Lower EE, Baughman RP. Predictors of Mortality in Pulmonary Sarcoidosis. Chest. 2018;153:105–13.
pubmed: 28728933
doi: 10.1016/j.chest.2017.07.008
Huitema MP, Bakker ALM, Mager JJ, Rensing BJWM, Smits F, Snijder RJ, et al. Prevalence of pulmonary hypertension in pulmonary sarcoidosis: the first large European prospective study. Eur Respir J. 2019;54:1900897.
pubmed: 31320453
doi: 10.1183/13993003.00897-2019
Pabst S, Grohé C, Skowasch D. Prevalence of sarcoidosis-associated pulmonary hypertension: cumulative analysis of two PULSAR studies. Eur Respir J. 2020;55:1902223.
pubmed: 32051184
doi: 10.1183/13993003.02223-2019
Baughman RP, Field S, Costabel U, Crystal RG, Culver DA, Drent M, et al. Sarcoidosis in America. Analysis based on Health Care Use. Ann Am Thorac Soc. 2016;13:1244–52.
pubmed: 27509154
doi: 10.1513/AnnalsATS.201511-760OC
Shorr AF, Helman DL, Davies DB, Nathan SD. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J. 2005;25:783–8.
pubmed: 15863633
doi: 10.1183/09031936.05.00083404
Boucly A, Cottin V, Nunes H, Jaïs X, Tazi A, Prévôt G, et al. Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. Eur Respir J. 2017;50:1700465.
pubmed: 29051269
doi: 10.1183/13993003.00465-2017
Kacprzak A, Tomkowski W, Szturmowicz M. Phenotypes of Sarcoidosis-Associated Pulmonary Hypertension—A challenging mystery. Diagnostics. 2023;13:3132.
pubmed: 37835874
pmcid: 10572558
doi: 10.3390/diagnostics13193132
Mathijssen H, Huitema MP, Bakker ALM, Smits F, Mager JJ, Snijder RJ, et al. Clinical phenotypes of Sarcoidosis-Associated Pulmonary Hypertension. Heart Lung Circ. 2021;30:1502–8.
pubmed: 33933365
doi: 10.1016/j.hlc.2021.03.279
Lichtblau M, Mayer L, Gopalan D, Dorfmüller P, Ulrich S. Clinical–radiological–pathological correlation in pulmonary hypertension with unclear and/or multifactorial mechanisms. Eur Respir Rev. 2023;32:230119.
pubmed: 38123234
pmcid: 10731469
doi: 10.1183/16000617.0119-2023
Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023;61:2200879.
pubmed: 36028254
doi: 10.1183/13993003.00879-2022
Baughman RP, Shlobin OA, Wells AU, Alhamad EH, Culver DA, Barney J, et al. Clinical features of sarcoidosis associated pulmonary hypertension: results of a multi-national registry. Respir Med. 2018;139:72–8.
pubmed: 29858005
doi: 10.1016/j.rmed.2018.04.015
Kacprzak A, Szturmowicz M, Burakowska B, Franczuk M, Kober J, Kurzyna M, et al. Sarcoidosis-Associated Pulmonary Hypertension treated with Sildenafil. Adv Respir Med. 2017;85:258–63.
pubmed: 29083021
doi: 10.5603/ARM.a2017.0043
Huitema MP, Mathijssen H, Mager JJ, Snijder RJ, Grutters JC, Post MC. Sarcoidosis-Associated Pulmonary Hypertension. Semin Respir Crit Care Med. 2020;41:659–72.
pubmed: 32777851
doi: 10.1055/s-0040-1713615
Savale L, Huitema M, Shlobin O, Kouranos V, Nathan SD, Nunes H, et al. WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension. Eur Respir Rev. 2022;31:210165.
pubmed: 35140103
pmcid: 9489049
doi: 10.1183/16000617.0165-2021
Bernaudin J-F, Le Pavec J, Fadel E, Jeny F, Valeyre D. Thomas De Montpreville V. Intimal granulomatous angiitis in sarcoid pulmonary vasculitis: worth remembering. ERJ Open Res. 2023;9:00549–2022.
pubmed: 37143848
pmcid: 10152265
doi: 10.1183/23120541.00549-2022
Shlobin OA, Baughman RP. Sarcoidosis-Associated Pulmonary Hypertension. Semin Respir Crit Care Med. 2017;38:450–62.
pubmed: 28750460
doi: 10.1055/s-0037-1603767
Ota H, Sugino K, Uekusa T, Takemura T, Homma S. An autopsy case of refractory pulmonary hypertension with sarcoidosis. Respir Investig. 2016;54:490–3.
pubmed: 27886864
doi: 10.1016/j.resinv.2016.05.005
Labyk A, Wretowski D, Zybińska-Oksiutowicz S, Furdyna A, Ciesielska K, Piotrowska-Kownacka D, et al. Balloon pulmonary angioplasty – efficient therapy of chronic thromboembolic pulmonary hypertension in the patient with advanced sarcoidosis – a case report. BMC Pulm Med. 2018;18:139.
pubmed: 30115061
pmcid: 6097314
doi: 10.1186/s12890-018-0695-4
Parikh KS, Dahhan T, Nicholl L, Ruopp N, Pomann G-M, Fortin T, et al. Clinical features and outcomes of patients with sarcoidosis-associated pulmonary hypertension. Sci Rep. 2019;9:4061.
pubmed: 30858405
pmcid: 6411962
doi: 10.1038/s41598-019-40030-w
Shlobin OA, Kouranos V, Barnett SD, Alhamad EH, Culver DA, Barney J et al. Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry. Eur Respir J. 2020;55.
Nathan SD, Barbera JA, Gaine SP, Harari S, Martinez FJ, Olschewski H, et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J. 2019;53:1801914.
pubmed: 30545980
pmcid: 6351338
doi: 10.1183/13993003.01914-2018
Shorr AF, Davies DB, Nathan SD. Outcomes for patients with sarcoidosis awaiting lung transplantation. Chest. 2002;122:233–8.
pubmed: 12114364
doi: 10.1378/chest.122.1.233
Bax S, Bredy C, Kempny A, Dimopoulos K, Devaraj A, Walsh S, et al. A stepwise composite echocardiographic score predicts severe pulmonary hypertension in patients with interstitial lung disease. ERJ Open Res. 2018;4:00124–2017.
pubmed: 29750141
pmcid: 5934528
doi: 10.1183/23120541.00124-2017
Nunes H, Humbert M, Capron F, Brauner M, Sitbon O, Battesti J, et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax. 2006;61:68–74.
pubmed: 16227329
doi: 10.1136/thx.2005.042838
Baughman RP, Engel PJ, Taylor L, Lower EE. Survival in Sarcoidosis-Associated Pulmonary Hypertension: the importance of hemodynamic evaluation. Chest. 2010;138:1078–85.
pubmed: 20348196
doi: 10.1378/chest.09-2002
Bandyopadhyay D, Humbert M. An update on sarcoidosis-associated pulmonary hypertension. Curr Opin Pulm Med. 2020;26:582.
pubmed: 32740377
doi: 10.1097/MCP.0000000000000701
Ungprasert P, Crowson CS, Matteson EL. Association of Sarcoidosis with increased risk of VTE. Chest. 2017;151:425–30.
pubmed: 27687848
doi: 10.1016/j.chest.2016.09.009
Goljan-Geremek A, Geremek M, Puscinska E, Sliwinski P. Venous thromboembolism and sarcoidosis: co-incidence or coexistence? Cent-Eur J Immunol. 2015;40:477–80.
pubmed: 26862313
doi: 10.5114/ceji.2015.56972
Takemura T, Matsui Y, Oritsu M, Akiyama O, Hiraga Y, Omichi M, et al. Pulmonary vascular involvement in sarcoidosis: granulomatous angiitis and microangiopathy in transbronchial lung biopsies. Virchows Arch A. 1991;418:361–8.
doi: 10.1007/BF01600167
Takemura T, Matsui Y, Saiki S, Mikami R. Pulmonary vascular involvement in sarcoidosis: a report of 40 autopsy cases. Hum Pathol. 1992;23:1216–23.
pubmed: 1427751
doi: 10.1016/0046-8177(92)90288-E
Crawshaw AP, Wotton CJ, Yeates DGR, Goldacre MJ, Ho L-P. Evidence for association between sarcoidosis and pulmonary embolism from 35-year record linkage study. Thorax. 2011;66:447–447.
pubmed: 20837871
doi: 10.1136/thx.2010.134429
Geremek AG, Tomkowski W, Geremek M, Puścińska E, Małek G, Nowiński A, et al. Sarcoidosis as a risk factor for venous thromboembolism. Sarcoidosis Vasc Diffuse Lung Dis. 2017;34:170–8.
pubmed: 32476839
pmcid: 7170146
Larsson J, Graff P, Bryngelsson I-L, Vihlborg P. Sarcoidosis and increased risk of comorbidities and mortality in Sweden. Sarcoidosis Vasc Diffuse Lung Dis. 2020;37:104–35.
pubmed: 33093776
pmcid: 7569548
Johannesdottir SA, Horváth-Puhó E, Dekkers OM, Cannegieter SC, Jørgensen JOL, Ehrenstein V, et al. Use of glucocorticoids and risk of venous thromboembolism: a Nationwide Population-based case-control study. JAMA Intern Med. 2013;173:743–52.
pubmed: 23546607
doi: 10.1001/jamainternmed.2013.122
Ina Y, Takada K, Yamamoto M, Sato T, Ito S, Sato S. Antiphospholipid antibodies: a prognostic factor in Sarcoidosis? CHEST. 1994;105:1179–83.
Samaranayake CB, McCabe C, Wort SJ, Price LC. Sarcoidosis associated pulmonary hypertension: an update. Curr Opin Pulm Med. 2021;27:285–95.
pubmed: 34127623
doi: 10.1097/MCP.0000000000000793
Condado JF, Babaliaros V, Henry TS, Kaebnick B, Kim D, Staton GW. Pulmonary stenting for the treatment of sarcoid induced pulmonary vascular stenosis. Sarcoidosis Vasc Diffuse Lung Dis off J WASOG. 2016;33:281–7.
Kurzyna M, Darocha S, Koteja A, Pietura R, Torbicki A. Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. Postępy W Kardiologii Interwencyjnej Adv Interv Cardiol. 2015;11:1–4.
Banaszkiewicz M, Kurzyna P, Kubikowska N, Mucha M, Rudnik A, Gąsecka A, et al. Emerging role of Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Disease—insights from the 2022 ESC guidelines. J Clin Med. 2023;12:5336.
pubmed: 37629379
pmcid: 10455782
doi: 10.3390/jcm12165336
Wang A, Su H, Duan Y, Jiang K, Li Y, Deng M, et al. Pulmonary hypertension caused by Fibrosing Mediastinitis. JACC Asia. 2022;2:218–34.
pubmed: 36338410
pmcid: 9627819
doi: 10.1016/j.jacasi.2021.11.016
Garrana SH, Buckley JR, Rosado-de-Christenson ML, Martínez-Jiménez S, Muñoz P, Borsa JJ. Multimodality Imaging of Focal and diffuse Fibrosing Mediastinitis. Radiographics. 2019;39:651–67.
pubmed: 30951437
doi: 10.1148/rg.2019180143
Liu L, Xu J, Zhang Y, Fang L, Chai Y, Niu M, et al. Interventional therapy in sarcoidosis-associated pulmonary arterial stenosis and pulmonary hypertension. Clin Respir J. 2017;11:906–14.
pubmed: 26666961
doi: 10.1111/crj.12435
daSilva-deAbreu A, Bracamonte-Baran W, Condado JF, Babaliaros V, Tafur-Soto J, Mandras SA. Characteristics and outcomes of Pulmonary Angioplasty with or without stenting for Sarcoidosis-Associated Pulmonary Hypertension: systematic review and Individual Participant Data Meta-Analysis. Curr Probl Cardiol. 2021;46:100616.
pubmed: 32532452
doi: 10.1016/j.cpcardiol.2020.100616